載入中
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
前收盤價
US$1.15
−US$0.02 · -1.71%
盤中時間採用ET。市場資料可能有所延遲。
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
日內區間
目前US$1.15
52週區間
目前US$1.15
盤中時間採用ET。市場資料可能有所延遲。
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
日內區間
目前US$1.15
52週區間
目前US$1.15
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.92億 USD | 1.97億 USD | 1.85億 USD | 1.65億 USD | 1.39億 USD |
| 銷貨成本 | 5485.8萬 USD | 5813萬 USD | 5787.7萬 USD | 5457.5萬 USD | 4881.7萬 USD |
| 毛利 | 1.37億 USD | 1.39億 USD | 1.27億 USD | 1.1億 USD | 9057.9萬 USD |
| 銷售、一般及管理費用 | 1.02億 USD | 1.07億 USD | 9882.6萬 USD | 1.71億 USD | 5396.2萬 USD |
| 營業費用 | 1.02億 USD | 1.07億 USD | 9882.6萬 USD | 1.71億 USD | 5601.8萬 USD |
| 利息支出 | 1096.1萬 USD | 1100.1萬 USD | 636.3萬 USD | 404.7萬 USD | 167.3萬 USD |
| 折舊和攤銷 | 367萬 USD | 357.4萬 USD | 299.4萬 USD | 219.9萬 USD | 140萬 USD |
| 營業利益 | 3555.1萬 USD | 3161.1萬 USD | 2865.7萬 USD | −6072.2萬 USD | 3456.1萬 USD |
| 淨利 | 2704.5萬 USD | 315.7萬 USD | 331.6萬 USD | −96.9萬 USD | 3261.9萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI136.07萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF40.78萬0.00%954億 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS26.22萬0.00%338.69億 USD0.31%US$78.35+0.32%
U.S. Micro Cap Portfolio ETFDFMC14.55萬0.00%75.58億 USD0.43%US$57.813+0.20%
iShares Micro-Cap ETFIWC9.84萬0.01%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM4萬0.03%1.17億 USD0.73%US$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
